Rat / Mouse Insulin ELISA Kit

Insulin (INS) is a polypeptide hormone produced by pancreatic-cells and it is the primary regulator of the body's metabolism of glucose, fat and protein. With new biotech products, the role, structure and correlation of insulin with metabolic disorders were always popular subjects. Insulin contains two polypeptide chains (A and B) bonded to each other by disulfide bonds. This organization means that insulin remains unsurpassably stable and active in the body. Blood glucose controls insulin production and activity directly at the molecular level: as blood glucose rises, pancreatic -cells identify glucose and release insulin. Insulin attaches to IR on the target cell, which initiates downstream reactions that promote uptake and use of glucose and blood glucose. The molecular means by which cells respond to insulin signals are IRS- (insulin receptor substrate) and IRS-independent. In the IRS-dependent pathway, for one, IR binds to IRS and activates the PI3K and mitogen-activated protein kinase (MAPK) pathways. This is followed by PI3K-Akt, which pushes GLUT4 further to the cell surface and activates the production of glucose. In addition, it's also hypoglycemic in action, modulating enzyme activity to create more glycogen and inhibit gluconeogenesis. The MAPK signaling pathway controls cell proliferation and growth. These IRS-independent pathways include, for example, Src homology 2 proteins, heterotrimeric G protein Gq/11, and Cbl-associated protein (CAP). These channels work in all sorts of tissues, most famously regulating insulin activity along multiple channels in the liver and skeletal muscle to keep blood glucose stable.

Figure 1. Metabolic Pathways of Endogenous Insulin. (Source: Rosenstock J, et al., 2024)

Insulin and metabolic control are crucial in the pathogenesis of diabetes, including type 2 diabetes mellitus (T2DM), a common metabolic disease in which tissues are less sensitive to normal insulin or insulin resistance. Insulin resistance is a heterogeneous disease, and its causes involve abnormal lipid storage in the liver, in particular the abnormal transport of lipid metabolites such as diacylglycerols and ceramides through hepatocytes. Recent research has focused on regulation within the insulin signaling pathway in order to create new treatments that mimic physiological insulin response. For instance, blocking key proteins of the insulin signaling pathway, including protein tyrosine phosphatase 1B (PTP1B), the NF-B pathway, and dipeptidyl peptidase IV (DPPIV), partially restores insulin sensitivity and can boost glycemic control in diabetes patients. As further study was done, it became clearer that skeletal muscle plays a key role in insulin resistance, and that, at baseline, 70-80 per cent of insulin-induced glucose use occurs in skeletal muscles. The increase of fat oxidation and muscle mass, both of which will lower lipid accumulation, have been suggested as ways to boost insulin sensitivity. Insulin is involved in multiple glucose homeostasis functions: it helps to control glucose usage and storage as well as fat and protein. Insulin increases lipid production and reduces lipolysis in the adipocyte. When it comes to protein metabolism, insulin maintains nitrogen by encouraging protein production and inhibiting protein breakdown. Insulin also operates in the kidneys – for instance, by promoting glomerular filtration and blood flow – and this closely matches polymorphisms in the human insulin receptor substrate (IRS) genes. As insulin resistance increases, insulin stays high in the bloodstream, while insulin's physiological response is progressively reduced. As a consequence, diabetic patients often show low levels of the vascular protective factor NO, which can then attack endothelial cells and drive atherosclerosis.

In retrospect, insulin was invented a century and a half ago and has been used widely to treat diabetes. Though insulin cannot treat diabetes, it will lower blood sugar, making living with diabetes a lot easier. But there are some caveats to conventional insulin therapy: the drugs have to be injected regularly, and their effectiveness is often variable. Through biotechnology, scientists are working on novel insulin combinations and routes of administration to circumvent the limitations of existing insulin treatments. Long-acting insulin and oral insulin, for instance, are in the early stages of trials and will most likely provide diabetics with a convenient means of treatment. More importantly than diabetes, insulin is increasingly seen as a contributor to neurodegeneration and atherosclerosis. And since diminished brain insulin sensitivity is closely associated with neurodegenerative disorders like Alzheimer's, researchers now think insulin is a key regulator of learning and memory. Plus, insulin resistance over time worsens atherosclerosis, making you vulnerable to cardiovascular disease. Insulin therefore plays a significant blood-glucose regulator, but its role in the nervous and cardiovascular systems opens up new opportunities for the future. Last but not least, insulin as a basic bioactive polypeptide plays no comparable role in regulating metabolism, diabetes and preventing and curing disease. The more we know about insulin's function and signals, the better off we'll be with novel insulin treatments and non-injectable approaches to getting insulin into patients. The science of insulin is destined to continue to examine its physiological functions and pathological mechanisms within multiple systems in order to create more potent drugs that provide novel avenues for preventing and treating metabolic disorders like diabetes.

Rat and Mouse Insulin ELISA Kit
Insulin ELISA Kit
Rat/Mouse Insulin Detection Kit